Company intelligence / Profile preview

Cosmas Therapeutics Development

Southborough, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Cosmas Therapeutics is a biotechnology company focused on developing novel antibody-based therapies for the treatment of solid tumors. The company's lead program targets Endothelial cell-selective adhesion molecule (ESAM), a protein involved in vascular permeability and tumor metastasis. By inhibiting ESAM, Cosmas aims to disrupt the tumor microenvironment and prevent the spread of cancer cells. The company is currently in the pre-clinical stage of development, advancing its lead candidate toward IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Beyond the preview

Go deeper on Cosmas Therapeutics Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cosmas Therapeutics Development.

Explore the full profile